Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Statin Timing May Improve Heart Surgery Outcomes

By HospiMedica International staff writers
Posted on 28 Mar 2017
A new study suggests that statin use 24 hours or less preoperatively is associated with decreased 30-day all-cause mortality after coronary artery bypass graft (CABG) surgery.

Researchers at Baylor College of Medicine and the Texas Heart Institute conducted a retrospective study of 3,025 primary CABG surgery patients in order to examine the effect of preoperative statin administration on mortality risk. More...
The patients were divided into three groups, according to timing of preoperative statin: 24 hours or less (1,788 patients), 24-72 hours (452 patients), or more than 72 hours before surgery or no dose (781 patients). The patients were then regrouped by preoperative dose: no statin (739 patients), 20 mg or less (920 patients), or more than 20 mg (1,284 patients).

The results showed that 30-day all-cause mortality was significantly lower for patients taking statin 24 hours or less preoperatively (1.7%), compared with 24-72 hours (2.9%), and more than 72 hours or no dose (3.8%). For preoperative statin dose, 30-day all-cause mortality was significantly lower when taking 20 mg or less (1.8%) or more than 20 mg statin (2.1%) than when taking none (3.8%). A statin dose of 20 mg preoperatively was associated with a 68% reduction of 30-day all-cause mortality; however, a 20 mg or less preoperative dose showed no mortality reduction. The study was published on March 16, 2017, in The Annals of Thoracic Surgery.

“Patients frequently forget to take their pills on the day of surgery, or they've been told to stop certain medications,” said senior author cardiovascular anesthesiologist Wei Pan, MD, of the Texas Heart Institute. “This study shows that not taking your statin for even one day before cardiac surgery may increase your risk of death after surgery. Based on our findings, we would advise patients to continue taking their statin medication all the way up to and including the day of surgery.”

According to the U.S. Centers for Disease Control and Prevention, cholesterol-lowering medication is used by 28% of Americans over the age of 40, and statins account for more than 90% of these drugs. Statins also have immunomodulatory and peripheral anti-inflammatory properties that are independent of their lipid-lowering action, which could explain their effect following CABG surgery, which is associated with an intense systemic inflammatory response linked to a range of postoperative complications.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.